AN0222

AN0222 is an investigational small molecule glucagon-like peptide 1 receptor (GLP-1R) agonist being developed by Beijing Anlong Biomedical for the treatment of obesity. Currently in the IND-enabling phase of development, the program is designed to provide a potent oral alternative to existing injectable GLP-1 therapies. By targeting the GLP-1 pathway, AN0222 is intended to regulate appetite and glucose metabolism, offering a more convenient dosing regimen for long-term weight management. The drug is a key component of Anlong's metabolic disease pipeline, which focuses on addressing high-prevalence conditions through innovative small molecule and nucleic acid platforms.